IL6 and steatosis: Simulations of a clinical protocol of tocilizumab in BIOLOGXsym leveraging the mechanistic toxicity data from LAMPS (i.e., induction of steatosis and ROS) and blockade of IL-6 signaling reproduced clinically observed and modest ALT elevations.